Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Paradigm Biopharmaceuticals ( (AU:PAR) ) is now available.
Paradigm Biopharmaceuticals has completed a US$5 million drawdown under its US$27 million Convertible Note Facility with Obsidian Global Partners. This funding will support the company’s global Phase 3 clinical trial for knee osteoarthritis, as it expands operations with new trial sites in Europe and Asia. The drawdown ensures Paradigm remains well-capitalized during this period of increased clinical activity, with US$15 million still available for future needs. The company maintains disciplined financial management to align investments with trial progress, ensuring funding through key milestones, including an interim analysis in mid-2026.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Ltd. is a late-stage drug development company focused on improving patient health and quality of life through the discovery, development, and delivery of pharmaceutical therapies. The company is currently concentrating on developing injectable pentosan polysulfate sodium (iPPS) for the treatment of diseases where inflammation plays a significant role, such as osteoarthritis.
YTD Price Performance: -9.33%
Average Trading Volume: 1,119,134
Technical Sentiment Signal: Sell
Current Market Cap: A$145.7M
Find detailed analytics on PAR stock on TipRanks’ Stock Analysis page.